Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 287 publications over 29 distinct years, with a maximum of 29 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	1	0	1
1992	1	0	1
1994	1	1	2
1995	0	1	1
1996	1	0	1
1997	3	1	4
1998	0	1	1
1999	0	1	1
2000	0	2	2
2001	1	2	3
2002	1	3	4
2003	5	4	9
2004	0	3	3
2005	4	3	7
2006	2	2	4
2007	6	6	12
2008	6	2	8
2009	5	8	13
2010	5	6	11
2011	9	11	20
2012	13	5	18
2013	13	11	24
2014	15	14	29
2015	11	9	20
2016	17	11	28
2017	13	10	23
2018	6	10	16
2019	5	5	10
2020	6	5	11

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Yarla NS, Madka V, Pathuri G, Rao CV. Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials. Int J Mol Sci. 2020 Dec 17; 21(24).

View in: PubMed
Bi WL, Gupta S, Mei Y, Abdulmohsen SA, Giantini Larsen A, Unadkat P, Ramkissoon S, Abedalthagafi M, Dunn IF. Immunophenotype of Vestibular Schwannomas. Otol Neurotol. 2020 12; 41(10):e1290-e1296.

View in: PubMed
Rischin D, Gil-Martin M, González-Martin A, Braña I, Hou JY, Cho D, Falchook GS, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos KP, Baranda J, Fury W, Feng M, Stankevich E, Li J, Yama-Dang NA, Yoo SY, Lowy I, Mathias M, Fury MG. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 11; 159(2):322-328.

View in: PubMed
Tripathi A, Balakrishna P, Agarwal N. PARP inhibitors in castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100199.

View in: PubMed
Raguraman R, Parameswaran S, Kanwar JR, Vasudevan M, Chitipothu S, Kanwar RK, Krishnakumar S. Gene expression profiling of tumor stroma interactions in retinoblastoma. Exp Eye Res. 2020 08; 197:108067.

View in: PubMed
Zheng W, Goodman AL, Velázquez Vega JE, Yin F, Fung KM, Osunkoya AO. Metastatic Renal Cell Carcinoma to the Brain: A Contemporary Clinicopathologic Analysis With Comparison of Immunohistochemical Profiles to Selected Primary Brain Tumors With Clear Cell Features. Appl Immunohistochem Mol Morphol. 2020 May/Jun; 28(5):395-402.

View in: PubMed
Yan J, Yu S, Jia C, Li M, Chen J. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges. Biochim Biophys Acta Rev Cancer. 2020 08; 1874(1):188367.

View in: PubMed
Dawson NA, Zibelman M, Lindsay T, Feldman RA, Saul M, Gatalica Z, Korn WM, Heath EI. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Mol Cancer Ther. 2020 06; 19(6):1373-1382.

View in: PubMed
Blessing NW, Bermudez-Magner JA, Fernandez MP, Rosenberg AE, Dubovy SR, Johnson TE. Solitary Fibrous Tumor of the Orbit: A Case Series With Clinicopathologic Correlation and Evaluation of STAT6 as a Diagnostic Marker. Ophthalmic Plast Reconstr Surg. 2020 Mar/Apr; 36(2):164-171.

View in: PubMed
Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clin Cancer Res. 2020 03 15; 26(6):1288-1296.

View in: PubMed

People

Explore

Similar Concepts

Top Journals